TrialBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2022

Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog

Thomas C Blevins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.